Biologic TNF-α Inhibitors for Stevens–Johnson Syndrome, Toxic Epidermal Necrolysis, and TEN-SJS Overlap: A Study-Level and Patient-Level Meta-Analysis-Reference-Cited by-同舟云学术

Biologic TNF-α Inhibitors for Stevens–Johnson Syndrome, Toxic Epidermal Necrolysis, and TEN-SJS Overlap: A Study-Level and Patient-Level Meta-Analysis

Published:2023-05-13 Issue:6 Volume:13 Page:1305-1327
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Cao Jiali,Zhang Xuan,Xing Xinzhu,Fan Jie

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13555-023-00928-w.pdf

Reference80 articles.

1. Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. J Plast Reconstr Aesthet Surg. 2016;69(6):e119–53.

2. Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, Shear NH. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16(6):475–93.

3. Yang MS, Lee JY, Kim J, et al. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis: a nationwide population-based study using national health insurance database in Korea. PLoS One. 2016;11(11): e0165933.

4. Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136(7):1387–97.

5. Chaby G, Maldini C, Haddad C, et al. Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis) in France during 2003–16: a four-source capture-recapture estimate. Br J Dermatol. 2020;182(3):618–24.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ocular involvement in Steven-Johnson syndrome/toxic epidermal necrolysis: recent insights into pathophysiology, biomarkers, and therapeutic strategies;Current Opinion in Ophthalmology;2024-08-13

2. Necrólisis epidérmica tóxica secundaria a voriconazol tratada con infliximab: primer caso pediátrico;Piel;2024-08

3. Advances in Clinical Pharmacogenomics and Prevention of Severe Cutaneous Adverse Drug Reactions in the Era of Precision Medicine;Personalized Medicine - New Perspectives [Working Title];2024-07-17

4. Greater mechanistic understanding of the cutaneous pathogenesis of Stevens–Johnson syndrome/toxic epidermal necrolysis can shed light on novel therapeutic strategies: a comprehensive review;Current Opinion in Allergy & Clinical Immunology;2024-05-17

5. Retrospective evaluation of a TEN/SJS series managed with a new treatment protocol;Journal of the European Academy of Dermatology and Venereology;2024-05-07